Related Experiment Video
Updated: Feb 16, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Evolving concepts in dilated cardiomyopathy
Marco Merlo1, Antonio Cannatà1, Marco Gobbo1
1Cardiovascular Department 'Ospedali Riuniti' and University of Trieste, Trieste, Italy.
Insights
Dilated cardiomyopathy (DCM) is a genetic heart failure often affecting young people. Advances improve prognosis, but key management questions regarding diagnosis, genotype-phenotype links, and arrhythmia risk remain.
Area of Science:
- Cardiology
- Genetics
- Heart Failure
Background:
- Dilated cardiomyopathy (DCM) is a primary cause of systolic heart failure, often with a genetic basis.
- It typically affects younger individuals with minimal comorbidities.
- Prognosis has improved due to better etiological understanding and integrated care.
Purpose of the Study:
- To provide a comprehensive review of current clinical management of DCM.
- To address unresolved issues in DCM diagnosis and risk stratification.
- To offer practical recommendations for managing DCM.
Main Methods:
- Literature review of recent advancements in DCM.
- Analysis of emerging issues in clinical management.
- Synthesis of evidence for practical recommendations.
Main Results:
- DCM management has advanced through etiological characterization and systematic screening.
- Key challenges persist in cardiac magnetic resonance utility, genotype-phenotype correlations, and arrhythmia risk assessment.
- The dynamic nature of DCM necessitates ongoing treatment optimization.
Conclusions:
- Despite improved outcomes, critical management aspects of DCM require further investigation.
- Addressing unresolved issues like advanced imaging and genetic insights is crucial.
- Continuous optimization of evidence-based treatments is essential for DCM patients.
Abstract:
Dilated cardiomyopathy (DCM) represents a particular aetiology of systolic heart failure that frequently has a genetic background and usually affects young patients with few co-morbidities. The prognosis of DCM has improved substantially during the last decades due to more accurate aetiological characterization, the red-flag integrated approach to the disease, early diagnosis through systematic familial screening, and the concept of DCM as a dynamic disease requiring constant optimization of medical and non-pharmacological evidence-based treatments. However, some important issues in clinical management remain unresolved, including the role of cardiac magnetic resonance for diagnosis and risk categorization and the interaction between genotype and clinical phenotype, and arrhythmic risk stratification. This review offers a comprehensive survey of these and other emerging issues in the clinical management of DCM, providing where possible practical recommendations.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure II: Pathophysiology
Cardiomyopathy IV: Restrictive Cardiomyopathy

